Search J Rheum

Advanced Search

Home

Current Issue

Archives

Guidelines for Authors & Reviewers

Classified Ads

Links

Search PubMed

Subscriptions

Subscriber Registration

Guidelines for Website Users

JRheum Update Service

Contact Info


Download PDF


View Table of Contents

Gout in Ambulatory Care Settings in the United States

ESWAR KRISHNAN, DOUGLAS LIENESCH, and C. KENT KWOH

ABSTRACT.

Objective.
To describe the ambulatory care utilization by patients with gouty arthritis (gout) in the United States using a nationally representative sample.

Methods. A cross-sectional survey design based on the ambulatory care data from the 2002 US National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey was used to examine the ambulatory care burden for gout, the characteristics of gout patients, the types of providers who see gout patients, and prescribing patterns associated with the management of gout. Weighted analyses were performed to estimate the effect of age, sex, and ethnicity on the association with gout and prescription of allopurinol.

Results. Of the 973 million ambulatory care visits in the United States, 3.9 million were for gout. The majority of visits were for men. The average age for men with gout was lower than that for women with gout (65 vs 70 years of age). Over two-thirds of these gout visits were attended to by primary care providers, whereas visits to rheumatologists constituted only a very small proportion of these visits (1.3%). There were 2.8 million prescriptions for allopurinol, 700,000 prescriptions for nonsteroidal antiinflammatory drugs, 381,000 prescriptions for colchicine, and 341,000 prescriptions for prednisone. After adjusting for age and sex, Asians were 2.7 times more likely than Caucasians to have a gout visit. Yet these patients had lower probability of receiving allopurinol (odds ratio 0.04, 95% confidence interval 0.01–0.27).

Conclusion. The majority of patients with gout are seen by generalist physicians. Asian ethnicity is associated with higher number of visits for gout, but a lower frequency of allopurinol treatment. (First Release Feb 1 2008; J Rheumatol 2008;35:498-501)

Key Indexing Terms:

GOUT
PHARMACOEPIDEMIOLOGY
ETHNICITY
ANTIINFLAMMATORY
ALLOPURINOL


From the Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; and Pittsburgh Veterans Affairs Healthcare System, Pittsburgh, Pennsylvania, USA.

Supported in part by TAP Pharmaceutical Products Inc., Lake Forest, IL, USA.

Dr. Krishnan is supported by a NIH Roadmap Multidisciplinary Clinical Research Career Development Award Grant (K12 RR023267) from the National Institutes of Health.

E. Krishnan, MD, MPH, Assistant Professor; D. Lienesch, MD, Department of Medicine, University of Pittsburgh; C.K. Kwoh, MD, Department of Medicine, University of Pittsburgh, and Pittsburgh VA Healthcare System.

Address reprint requests to Dr. E. Krishnan, Department of Medicine, University of Pittsburgh, S709 Biomedical Science Tower, 3500 Terrace Street, Pittsburgh, PA 15261. E-mail: Arthritis.MD@gmail.com

Accepted for publication November 2, 2007.




Return to March 2008 Table of Contents



© The Journal of Rheumatology Publishing Company Limited.
All rights reserved.